Navigation Links
Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Date:3/10/2008

Company to host conference call Today, Monday, March 10, 2008 at 8:30am

NEW YORK, March 10 /PRNewswire-FirstCall/ -- On Friday, March 7, 2008, Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), announced top-line results from its SUN-MICRO Phase 3 clinical trial of Sulonex (sulodexide) for the treatment of diabetic nephropathy. The Company announced that this Phase 3 clinical trial failed to meet the primary objective of the study, which was to increase the proportion of patients that achieve therapeutic success at 6 months as compared to placebo over background therapy of maximal doses of ACE-inhibitors or ARBs. Therapeutic success was defined as (i) conversion from microalbuminuria to normoalbuminuria, as measured by albumin/creatinine ratio (ACR), with at least a 25% reduction in ACR relative to baseline ACR, or (ii) a 50% reduction in ACR relative to baseline ACR. In addition, in reviewing the mean changes in ACR over time, Sulonex and placebo appeared to be similar.

Michael S. Weiss, the Company's Chairman and Chief Executive Officer, commented, "We are all very disappointed with the outcome of this Study. While this represents the end of one chapter for Keryx, it is not the end of Keryx. Drug development is inherently risky and, accordingly, we have spent the last several years building what we believe to be a promising product portfolio in the event our lead drug failed. We plan to re-focus our primary efforts and resources on rapidly moving Zerenex forward for ESRD patients with hyperphosphatemia and Perifosine forward for cancer. Our goal is to have Perifosine in a pivotal program this year and be well into our Zerenex high- dose Phase 2 trial before the end of the year."

In order to participate in this morning's c
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
3. Keryx Biopharmaceuticals Announces Additions to Management Team
4. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
5. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
6. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
7. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
8. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
9. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
10. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
11. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Freeslate, Inc ., the leading ... Lupin Limited, one of India’s top five pharmaceutical companies, ... System for high throughput solid form screening. ... a wide range of quality, affordable generic and branded ...
(Date:1/14/2014)... 14, 2014 Histogen, Inc., a regenerative ... cells grown under simulated embryonic conditions, today announced that ... Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s ... This agreement is an amendment to the existing license ...
(Date:1/14/2014)... Md. , Jan. 14, 2014  Organovo announced today ... the National Institutes of Health (NIH) to help scientists ... treatments to patients on a faster timeline. Organovo is ... (NCATS) and the National Eye Institute (NEI) to develop ...
(Date:1/14/2014)... Kinaxis ®, provider of RapidResponse ®, a cloud-based supply ... ( S&OP ) service, is proud to be a gold ... held at the Hilton San Diego Bayfront, January 30 – ... Kaszas , Director of Supply Chain at Amgen, as she ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that ... company update at the Deutsche Bank 34th Annual Health Care ... p.m. ET. Interested parties may access a live audio ... the BioMarin website, www.BMRN.com . A ...
... platform for treatment of Spinal Muscular Atrophy SOUTH PLAINFIELD, ... Inc. (PTC) and the Spinal Muscular Atrophy (SMA) Foundation ... which the SMA Foundation will provide up to $8.5 ... second continuation of the collaboration to fund a series ...
... AND STRENGTHENS ITS SENIOR MANAGEMENT TEAM , ... Systems, Inc. (OTC Bulletin Board: OMCM.OB), a leader in ... today announced that it has strengthened its European presence ... Summa. As Executive Vice President, Europe & Asia/Pacific based ...
Cached Biology Technology:BioMarin to Present at the Deutsche Bank Health Care Conference 2PTC Therapeutics and Spinal Muscular Atrophy Foundation Announce $8.5 Million Small Molecule Development Collaboration 2PTC Therapeutics and Spinal Muscular Atrophy Foundation Announce $8.5 Million Small Molecule Development Collaboration 3OmniComm Systems Appoints EDC Veteran Dr. Wolfgang Summa to Executive Vice President, Europe & Asia/Pacific 2OmniComm Systems Appoints EDC Veteran Dr. Wolfgang Summa to Executive Vice President, Europe & Asia/Pacific 3
(Date:7/10/2014)... and teens living with a cardiac pacemaker, a low ... of life, reports a study in the July ... the official journal of the Society for Developmental ... by Lippincott Williams & Wilkins , a part ... function as a protective factor against lower health-related quality ...
(Date:7/10/2014)... image was collected by the Moderate Resolution Imaging Spectroradiometer ... Each hot spot, which appears as a red mark, ... MODIS instrument recognized temperatures higher than background. When accompanied ... hot spots are diagnostic for fire. , This ... coming directly from the fires, although the smoke released ...
(Date:7/10/2014)... some patients, the chronic inflammatory skin diseases psoriasis* and ... have therefore had to base their decision on which ... an examination of tissue samples. A team of researchers ... of Munich (TUM) have now analyzed the molecular processes ... This has enabled them for the first time to ...
Breaking Biology News(10 mins):For children with pacemakers, 'self-competence' affects quality of life 2New diagnostic test to distinguish psoriasis from eczema 2
... Science-based identification of mold and other causes of ... plant pathologists with The American Phytopathological Society (APS). ... situation in which building occupants experience health problems ... typically associated with SBS range from allergy attacks ...
... South Korean team announced last week that it had ... that were genetically matched to specific people. But their ... Yuri Verlinsky of the Reproductive Genetics Institute, based in ... without resorting to therapeutic cloning. "It would be a ...
... When genes are deleted on a particular section of ... the childhood cancer neuroblastoma. A new study suggests that ... children with neuroblastoma may indicate to physicians that they ... fight the cancer. , Edward F. Attiyeh, M.D., a ...
Cached Biology News:What's really making you sick? Plant pathologists offer the science behind Sick Building Syndrome 2Double triumph in stem cell quest 2Double triumph in stem cell quest 3Double triumph in stem cell quest 4Chromosome Deletion Predicts Aggressive Neuroblastoma 2
... Glutathion-S-Transferase-pi EIA Principle: Glutathion-S-transferases ... which are involved in the detoxification ... 5 subgroups: Alpha, Mu, Pi, Teta ... their physiochemical, immunological, enzymatic and s ...
... only microplate sealer with an integrated in-line ... with a variety of configurations and sealing ... integrated stacker and 240-plate storage capacity , ... in small workcells , Handles all SBS ...
... aptamer screening and binding optimization and built ... on-chip synthesis platform. These microarrays are available ... Microarray Service. Probe Content ... than 1500 known aptamer sequences. Add up ...
... Microarrays designed for RNA aptamer screening and ... and powerful Paraflo microfluidic on-chip synthesis platform. ... be synthesized on-chip and LC Sciences can ... microarrays are available as part of our ...
Biology Products: